311 related articles for article (PubMed ID: 19004541)
1. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
[TBL] [Abstract][Full Text] [Related]
2. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
[TBL] [Abstract][Full Text] [Related]
3. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
4. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
5. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Zhang HL; Zhu Y; Wang CF; Yao XD; Zhang SL; Dai B; Shen YJ; Zhu YP; Shi GH; Ye DW
Int J Urol; 2011 Jun; 18(6):422-30. PubMed ID: 21481012
[TBL] [Abstract][Full Text] [Related]
11. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Kamada P; Dudek AZ
Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Nozawa M; Yamamoto Y; Minami T; Shimizu N; Hatanaka Y; Tsuji H; Uemura H
BJU Int; 2012 Sep; 110(6 Pt B):E228-34. PubMed ID: 22332735
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
17. Molecule of the month. Sorafenib.
Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
[No Abstract] [Full Text] [Related]
18. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Bukowski RM
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
